Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear.
introduction Rituximab, a chimeric anti-CD20 antibody, is highly effective in the treatment of various types of CD20-positive B-cell lymphomas [1, 2] . It has been reported that complementdependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and the induction of apoptosis are the major mechanisms of action for rituximab [3, 4] . A significantly improved outcome has been obtained in young and elderly patients by combining cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with rituximab [5] [6] [7] .
3-Hydroxy-3-methylgutaryl coenzyme A reductase inhibitors, commonly known as statins, inhibit the ratelimiting step of the mevalonate pathway, which is essential for the biosynthesis of various compounds, including cholesterol [8] . The activity of rituximab may be reduced by conformational changes in CD20 induced by the depletion of serum cholesterol, which impairs rituximab binding and thereby significantly decreases rituximab-mediated CDC and ADCC against B-cell lymphoma cells [9] .
Several authors have cited the same laboratory study [10] [11] [12] and these in vitro data have led some to recommend that statins might not be used when patients are being treated with rituximab. However, it is unclear whether statins actually affect the prognosis of diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). The aim of this study was to assess the influence of statin use on the outcome of patients with RCHOP-treated DLBCL.
patients and methods

patient characteristics
We reviewed the medical records of patients with DLBCL who received RCHOP as a first-line therapy at the Cancer Institute Hospital and Okayama University Hospital between April of 2004 and May of 2008 and were followed up until January of 2009. In this period, the patients with statin use and the patients without statin use treated in the same time frame as the patients with statin-use group were analyzed. The definition of the patients with statin use was the patients who had been taking statins for at least 2 months at the start of RCHOP. The study protocol for this retrospective analysis was approved by the institutional review boards of both hospitals. Patients were analyzed if they were older than 18 years and had a performance status (PS) of zero to three according to the criteria of the Eastern Cooperative Oncology Group. Patients were excluded if they were positive for antibodies against human immunodeficiency virus-1 or -2. Patients with primary mediastinal large B-cell lymphoma, primary central nervous system lymphoma, or primary testicular lymphoma were also excluded from this study.
The disease stage was evaluated according to the Ann Arbor staging system. All patients had undergone staging investigations, including physical examinations, blood and serum analyses, bone marrow aspiration and biopsy, and computed tomography (CT) of the neck, chest, abdomen, and pelvis. Magnetic resonance imaging was used to evaluate involved organs in the head and neck. Some patients underwent positron emission tomography (PET)/CT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose for staging evaluation and assessing treatment response. Chemotherapy sensitivity was defined according to standard volume criteria using CT and PET/CT imaging [13, 14] .
The following clinical and laboratory information was available at the time of diagnosis: history of statin treatment; age; sex; PS; stage; number of extranodal sites; and serum levels of lactate dehydrogenase, total cholesterol (T-cho), triglycerides, and high-density lipoprotein cholesterol. This information allowed the determination of International Prognostic Index (IPI) scores for the included patients. Patients were categorized into either low-risk (IPI score 0-2) or high-risk (IPI score 3-5) groups. The serum cholesterol level was considered 'high' when higher than the median serum T-cho and 'low' when lower than the median serum T-cho.
pathological studies
Biopsied samples collected before treatment were fixed in formalin, embedded in paraffin, sectioned, and then stained with hematoxylin and eosin for morphological analysis. All diagnoses were made according to the World Health Organization classification [15] . Cases involving transformed low-grade/indolent B-cell lymphoma were excluded. All the samples were reviewed by expert hematopathologists (KT and TY).
treatment
For patients with stage IB-IV, rituximab was administered at the standard dose of 375 mg/m 2 in 8-week cycles during the first and second cycles of CHOP or six triweekly cycles concurrent with each of the six cycles of triweekly CHOP, as described previously [16] . Patients with stage IA were treated with three cycles of CHOP with subsequent radiotherapy; rituximab was administered in 8-week cycles during the first and second cycles of CHOP or three triweekly cycles concurrent with each of the three cycles of triweekly CHOP.
statistical analysis
Progression-free survival (PFS) was calculated from the date of RCHOP initiation to the date of documented disease progression, relapse, or the end date of the study. Overall survival (OS) was calculated from the date of RCHOP initiation until death from any cause or the last follow-up. If the stop date was not reached, the data were censored at the date of the last follow-up evaluation. Survival curves were created by the Kaplan-Meier method; overall differences were compared by the log-rank test. original article Annals of Oncology daily every day. The serum T-cho level tended to be higher for those patients taking statins than for those patients not using statins; however, the difference was not statistically significant. No significant difference was found between the two groups in terms of their basic characteristics except for sex: females were the dominant statin users. The complete remission rate was not significantly different between the patients with (74%) and without (73%) statin use. With a median follow-up of 32 months (range 7-57 months), the Kaplan-Meier method revealed that the 3-year PFS rates were 84% and 73%, while the OS rates were 89% and 78% for the groups with and without statin use, respectively. Although both survival rates were superior in the statin group, the differences were not statistically significant (P = 0.38 and 0.28, respectively; Figure 1A and B) . Similarly, the PFS and OS rates at 3 years were 75% and 87%, respectively, for the lowcholesterol group and 85% and 90%, respectively, for the highcholesterol group; no significant differences in these parameters were observed between the two groups (P = 0.39 and P = 0.28, respectively). On the other hand, the 3-year PFS rates were 60% and 81% (P = 0.005), while the OS rates were 69% and 85% (P = 0.004) for the high-and low-IPI groups, respectively, and this result was not affected after adjusting for statin use (data not shown). There were no significant differences in PFS and OS between longer and shorter statin users who had statins for more and less than median duration, respectively (P = 0.58 and P = 0.94, respectively). To adjust for the prognostic value of serum cholesterol level and IPI, Cox multivariate analysis was carried out. As shown in Table 2 , statin use did not have a significant prognostic value either for PFS or OS after adjusting for serum cholesterol level. Of 26 deaths, 21 were caused by progressive disease, while two were caused by interstitial pneumonia, two by bacterial infection, and one by suicide; no patient died of a cardiovascular event.
discussion
Our data indicate no significant influence of statin use on prognosis in patients with DLBCL. Indeed, there is currently no report confirming the clinical significance of statins in patients treated with rituximab.
Our results do not support the previous laboratory data, and several explanations can be offered for these discrepancies. First, the cholesterol levels of the patients may not have been adequately lowered by the statin doses given. However, in this study, the general outcome was not affected even in the lowcholesterol group. Thus, it is important to determine the in vivo threshold level of cholesterol, if any, that affects the CD20 conformation reportedly required for rituximab-mediated CDC and ADCC [9] . Second, accumulating evidence indicates that statins have anticancer [17, 18] and antilymphoma activity [19, 20] . Therefore, statin use may have favorably influenced the RCHOP-treated DLBCL patients in this study. Third, several prognostic markers have been assessed and identified in patients with DLBCL treated with rituximab-combined chemotherapy [21] [22] [23] [24] . Consistent with recent findings [21, 22, 25] , the IPI score also had a prognostic impact on outcome in our cohort of patients who received immunochemotherapy; thus, biochemical markers and clinical prognostic factors may have greater predictive power than statin use.
Similar to statin use and serum cholesterol in this study, no prognostic marker other than IPI has been found to predict [26] [27] [28] [29] , some of which have been reassessed and shown to be unassociated with prognosis in patients treated with rituximab-combined chemotherapy [21] [22] [23] . BCL2 overexpression was reportedly associated with poorer survival in patients treated with CHOP-like regimens [26, 27] , but several studies failed to confirm its prognostic value in patients treated with rituximab-combined chemotherapy, indicating that the addition of rituximab overcomes the negative influence of BCL2 overexpression [23] . BCL6, a marker of germinal center derivation, has been identified as a marker of a favorable outcome in DLBCL [28] , but outcomes for patients treated with immunochemotherapy were not influenced by BCL6 status [21] . Similarly, no correlation was observed between the immunohistochemically defined GC phenotype and survival rate in patients receiving immunochemotherapy [29] , which is in contrast to previous findings of inferior outcomes in non-GC patients relative to GC patients in the pre-rituximab era [22] . Although our study was not a randomized, prospective study and was possibly biased by factors other than statin use, the distribution of baseline characteristics, including IPI factors, was similar between the groups. Unfortunately, the sample size of statin users was likely too small to reach any definitive conclusions. In this study HRs of statin use for PFS and OS were 0.85 and 0.52 without statistical significance. Post hoc statistical power calculation revealed that the statistical power for these HRs were 5.9% and 35.6%, respectively. Therefore, one may say that we need more studies to draw more solid conclusion. Furthermore, our analysis is based solely upon patients with DLBCL receiving RCHOP therapy and may not be generalizable to patients with other types of B-cell lymphoma or patients receiving rituximab alone.
In conclusion, we investigated the effects of statin use on clinical outcome in DLBCL patients receiving RCHOP and found that statin use did not influence their prognosis. To confirm this conclusion, larger scale, prospective studies of DLBCL patients are required.
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